Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Nicox

DB:NXOA
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NXOA
DB
€119M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Nicox has significant price volatility in the past 3 months.
NXOA Share Price and Events
7 Day Returns
5.2%
DB:NXOA
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-36.1%
DB:NXOA
-13.2%
DE Biotechs
-20.9%
DE Market
NXOA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nicox (NXOA) 5.2% -0.4% -19.5% -36.1% -64.4% -62.3%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • NXOA underperformed the Biotechs industry which returned -13.2% over the past year.
  • NXOA underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
NXOA
Industry
5yr Volatility vs Market

NXOA Value

 Is Nicox undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Nicox. This is due to cash flow or dividend data being unavailable. The share price is €3.61.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nicox's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nicox's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NXOA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.62
ENXTPA:COX Share Price ** ENXTPA (2020-04-03) in EUR €3.57
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nicox.

DB:NXOA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:COX Share Price ÷ EPS (both in EUR)

= 3.57 ÷ -0.62

-5.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nicox is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Nicox is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Nicox's expected growth come at a high price?
Raw Data
DB:NXOA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-10.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Nicox, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Nicox's assets?
Raw Data
DB:NXOA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.29
ENXTPA:COX Share Price * ENXTPA (2020-04-03) in EUR €3.57
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:NXOA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:COX Share Price ÷ Book Value per Share (both in EUR)

= 3.57 ÷ 3.29

1.09x

* Primary Listing of Nicox.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nicox is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Nicox's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Nicox has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NXOA Future Performance

 How is Nicox expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-10.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nicox expected to grow at an attractive rate?
  • Unable to compare Nicox's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Nicox's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Nicox's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NXOA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NXOA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -10.3%
DB:NXOA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 41.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NXOA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NXOA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 90 -5 -15 1
2023-12-31 20 -44 -54 1
2022-12-31 10 -45 -55 1
2021-12-31 31 -16 -25 2
2020-12-31 5 -21 -26 2
2020-04-06
DB:NXOA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -16 -19
2019-09-30 8 -19 -15
2019-06-30 9 -22 -11
2019-03-31 7 -21 -15
2018-12-31 4 -19 -18
2018-06-30 3 -12 -4
2018-03-31 2 -12 -6
2017-12-31 2 -12 -8
2017-06-30 0 -19 -6
2017-03-31 0 -22 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Nicox is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Nicox's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NXOA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Nicox Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NXOA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.43 -0.43 -0.43 1.00
2023-12-31 -1.58 -1.58 -1.58 1.00
2022-12-31 -1.62 -1.62 -1.62 1.00
2021-12-31 -0.75 -0.75 -0.75 1.00
2020-12-31 -0.77 -0.62 -0.92 2.00
2020-04-06
DB:NXOA Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.62
2019-09-30 -0.51
2019-06-30 -0.39
2019-03-31 -0.50
2018-12-31 -0.62
2018-06-30 -0.13
2018-03-31 -0.22
2017-12-31 -0.31
2017-06-30 -0.24
2017-03-31 -0.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Nicox is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Nicox's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nicox has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NXOA Past Performance

  How has Nicox performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nicox's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nicox does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Nicox's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Nicox's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Nicox's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nicox Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NXOA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.86 -18.92 7.67
2019-09-30 8.09 -15.21 8.39
2019-06-30 9.32 -11.49 9.12
2019-03-31 6.67 -14.94 9.31
2018-12-31 4.03 -18.39 9.51
2018-06-30 2.61 -3.78 8.90
2018-03-31 2.46 -6.04 9.38
2017-12-31 2.31 -8.30 9.87
2017-06-30 0.01 -6.00 9.22 -6.54
2017-03-31 0.01 -6.37 8.92 -3.27
2016-12-31 0.02 -6.74 8.62
2016-09-30 0.01 -14.53 9.04 5.21
2016-06-30 0.00 -22.32 9.46 10.42
2016-03-31 0.03 -21.03 10.16 8.29
2015-12-31 0.07 -19.75 10.87 6.16
2015-06-30 3.93 -21.19 20.44 4.92
2015-03-31 4.95 -21.59 22.30 4.68
2014-12-31 5.98 -21.99 24.16 4.43
2014-06-30 2.39 -13.31 13.72 3.49
2014-03-31 1.44 -12.67 12.93 3.58
2013-12-31 0.44 -11.37 11.43 3.63
2013-09-30 0.30 -19.24 14.65 4.69
2013-06-30 0.25 -19.09 12.68 5.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Nicox has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Nicox has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Nicox improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Nicox's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nicox has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NXOA Health

 How is Nicox's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nicox's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nicox is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nicox's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nicox's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nicox Company Filings, last reported 3 months ago.

DB:NXOA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 109.30 11.12 28.10
2019-09-30 109.30 11.12 28.10
2019-06-30 114.42 7.36 17.35
2019-03-31 114.42 7.36 17.35
2018-12-31 113.65 0.00 22.06
2018-06-30 122.24 0.00 32.69
2018-03-31 122.24 0.00 32.69
2017-12-31 126.77 0.00 41.39
2017-06-30 97.33 0.00 20.44
2017-03-31 97.33 0.00 20.44
2016-12-31 104.55 0.00 28.86
2016-09-30 104.55 0.00 28.86
2016-06-30 78.62 0.00 12.34
2016-03-31 78.62 0.00 12.34
2015-12-31 101.33 0.15 29.60
2015-06-30 119.22 19.50 39.53
2015-03-31 119.22 19.50 39.53
2014-12-31 96.28 0.32 31.87
2014-06-30 47.43 0.00 41.42
2014-03-31 47.43 0.00 41.42
2013-12-31 61.38 0.00 58.47
2013-09-30 62.00 0.00 63.78
2013-06-30 65.92 0.00 67.41
  • Nicox's level of debt (10.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.6% vs 10.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Nicox has sufficient cash runway for 1.7 years based on current free cash flow.
  • Nicox has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -10.5% each year.
X
Financial health checks
We assess Nicox's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nicox has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NXOA Dividends

 What is Nicox's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Nicox dividends.
If you bought €2,000 of Nicox shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Nicox's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Nicox's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NXOA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NXOA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Nicox has not reported any payouts.
  • Unable to verify if Nicox's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Nicox's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Nicox has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Nicox's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nicox afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nicox has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NXOA Management

 What is the CEO of Nicox's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michele Garufi
COMPENSATION €658,374
AGE 65
CEO Bio

Mr. Michele Garufi co-founded Nicox SA in 1996 and has been its Chief Executive Officer since February 15, 1996. Mr. Garufi is a co-founder of Scharper Ltd. He serves as an Administrator of Scharper SpA. He has an extensive experience in business development, licensing and international marketing in the European pharmaceutical industry. He served as the President at Nicox SA since February 15, 1996 until March 1996, he served as a Vice President of the Division International and Directing Licenses Activities at Recordati Italy and Managing Director of Recordati's subsidiary in Spain. Mr. Garufi served as Director of the International Division of Italfarmaco from 1988 to 1992, Assistant to the Chief Executive Officer of Polished Chimica from 1984 to 1988, Assistant to the President at Medea Research since 1983 and Technical Director of one of the Italian subsidiaries of the Lipha Group from 1978 to 1982. He co-founded Relivia Srl and serves as its Chairman. He serves as the Chairman of Nicox SA and has been its Director since February 15, 1996. He served as a Non-Executive Director of Novexel SA. He serves as a member of the Board of Scharper Srl. He serves as a Director of Lica Pharmaceuticals A/S. He served as an Independent Director of Novuspharma SpA. Mr. Garufi graduated with full honors in Pharmaceutical Chemistry from the University of Milan in 1977.

CEO Compensation
  • Michele's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Michele's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Nicox management team in years:

2
Average Tenure
52
Average Age
  • The average tenure for the Nicox management team is less than 2 years, this suggests a new team.
Management Team

Michele Garufi

TITLE
Co-Founder
COMPENSATION
€658K
AGE
65

Sandrine Gestin

TITLE
Vice President of Finance
AGE
52

Emmanuelle Pierry

TITLE
General Counsel & Head of Legal
TENURE
2.9 yrs

Gavin Spencer

TITLE
Executive VP
AGE
49
TENURE
1 yrs

Tomas Navratil

TITLE
Executive VP and Head of R&D
TENURE
3.3 yrs

Ramesh Krishnamoorthy

TITLE
Senior Director and Head of Late Stage CMC & Quality Control
TENURE
0.6 yrs

Ennio Ongini

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Nicox board of directors in years:

2.9
Average Tenure
66
Average Age
  • The average tenure for the Nicox board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michele Garufi

TITLE
Co-Founder
COMPENSATION
€658K
AGE
65

Labb Labbe

TITLE
Independent Director
COMPENSATION
€50K
AGE
69
TENURE
9.8 yrs

Adrienne Graves

TITLE
Independent Director
COMPENSATION
€50K
AGE
66
TENURE
5.7 yrs

Robert Fechtner

TITLE
Chairman of Clinical Advisory Board
TENURE
1.3 yrs

Luzi von Bidder

TITLE
Independent Director
COMPENSATION
€50K
AGE
66
TENURE
5.7 yrs

Les Kaplan

TITLE
Independent Director
COMPENSATION
€50K
AGE
69
TENURE
5.5 yrs

Lauren Silvernail

TITLE
Director
COMPENSATION
€50K
AGE
61
TENURE
2.9 yrs

Donald Budenz

TITLE
Member of Clinical Advisory Board
TENURE
1.3 yrs

Steven Mansberger

TITLE
Member of Clinical Advisory Board
TENURE
1.3 yrs

Helen DuBiner

TITLE
Member of Clinical Advisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Nicox's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nicox has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NXOA News

Simply Wall St News

NXOA Company Info

Description

Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning ocular congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors and NO-donating soluble guanylate cyclase stimulators. The company has collaborations with Bausch + Lomb, Astra Zeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.

Details
Name: Nicox S.A.
NXOA
Exchange: DB
Founded: 1996
€119,487,078
33,469,770
Website: http://www.nicox.com
Address: Nicox S.A.
Drakkar 2 – Bât D,
2405 route des Dolines,
Valbonne,
Provence-Alpes-Côte d'Azur, 06560,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA COX Ordinary Shares Euronext Paris FR EUR 03. Nov 1999
OTCPK NICX.F Ordinary Shares Pink Sheets LLC US USD 03. Nov 1999
DB NXOA Ordinary Shares Deutsche Boerse AG DE EUR 03. Nov 1999
LSE 0RCQ Ordinary Shares London Stock Exchange GB EUR 03. Nov 1999
BATS-CHIXE COXP Ordinary Shares BATS 'Chi-X Europe' GB EUR 03. Nov 1999
Number of employees
Current staff
Staff numbers
41
Nicox employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:01
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.